Evidence map›Paper›PMID 24368514›Full record

Trial reportAnnals of the rheumatic diseases2015

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

Iain B McInnes, Liz Thompson, Jon T Giles, Joan M Bathon, Jane E Salmon, Andre D Beaulieu, Christine E Codding, Timothy H Carlson, Christian Delles, Janet S Lee and 1 more

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 11 pooled it
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

169 citing papers in PubMed, 11 syntheses or guidelines pooled it, 320 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  14. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

109 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Iain B McInnesUniversity of Glasgow, Glasgow, UK.
Liz ThompsonRoche Products Ltd, Welwyn Garden City, UK.
Jon T GilesColumbia University, New York, New York, USA.
Joan M BathonColumbia University, New York, New York, USA.
Jane E SalmonHospital for Special Surgery-Weill Cornell Medical College, New York, New York, USA.
Andre D BeaulieuCentre Hospitalier de l'Université Laval, Quebec City, Quebec, Canada.
Christine E CoddingHealth Research of Oklahoma, Oklahoma City, Oklahoma, USA.
Timothy H CarlsonPacific Biomarkers, Seattle, Washington, USA.
Christian DellesUniversity of Glasgow, Glasgow, UK.
Janet S LeeRoche, Nutley, New Jersey, USA.
Naveed SattarUniversity of Glasgow, Glasgow, UK.
University of Glasgow · GBColumbia University · USCentre hospitalier de l'Université Laval · CACornell University · USLa Roche College · USPacific Biomarkers (United States) · USRoche (United Kingdom) · GBUniversity of Oklahoma Health Sciences Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe interleukin-6 receptor (IL-6R) blocker tocilizumab (TCZ) reduces inflammatory disease activity in rheumatoid arthritis (RA) but elevates lipid concentrations in some patients. We aimed to characterise the impact of IL-6R inhibition on established and novel risk factors in active RA.

methodsRandomised, multicentre, two-part, phase III trial (24-week double-blind, 80-week open-label), MEASURE, evaluated lipid and lipoprotein levels, high-density lipoprotein (HDL) particle composition, markers of coagulation, thrombosis and vascular function by pulse wave velocity (PWV) in 132 patients with RA who received TCZ or placebo.

resultsMedian total-cholesterol, low-density lipoprotein-cholesterol (LDL-C) and triglyceride levels increased in TCZ versus placebo recipients by week 12 (12.6% vs 1.7%, 28.1% vs 2.2%, 10.6% vs -1.9%, respectively; all p<0.01). There were no significant differences in mean small LDL, mean oxidised LDL or total HDL-C concentrations. However, HDL-associated serum amyloid A content decreased in TCZ recipients. TCZ also induced reductions (>30%) in secretory phospholipase A2-IIA, lipoprotein(a), fibrinogen and D-dimers and elevation of paraoxonase (all p<0.0001 vs placebo). The ApoB/ApoA1 ratio remained stable over time in both groups. PWV decreases were greater with placebo than TCZ at 12 weeks (adjusted mean difference 0.79 m/s (95% CI 0.22 to 1.35; p=0.0067)).

conclusionsThese data provide the first detailed evidence for the modulation of lipoprotein particles and other surrogates of vascular risk with IL-6R inhibition. When compared with placebo, TCZ induced elevations in LDL-C but altered HDL particles towards an anti-inflammatory composition and favourably modified most, but not all, measured vascular risk surrogates. The net effect of such changes for cardiovascular risk requires determination.

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, RheumatoidAryldialkylphosphataseCardiovascular DiseasesCholesterol, HDLCholesterol, LDLDouble-Blind MethodDyslipidemiasFemaleFibrin Fibrinogen Degradation ProductsFibrinogenGroup II Phospholipases A2HumansLipoprotein(a)Antibodies, Monoclonal, HumanizedAntirheumatic AgentsAryldialkylphosphataseCholesterol, HDLCholesterol, LDLFibrin Fibrinogen Degradation Productsfibrin fragment DFibrinogenGroup II Phospholipases A2IL6R protein, humanLipoprotein(a)Receptors, Interleukin-6Serum Amyloid A ProteintocilizumabTriglyceridesCardiovascular DiseaseDMARDs (biologic)InflammationLipidsRheumatoid Arthritis

Identifiers

PMID24368514
PMCPMC4392313
OpenAlexW2156166356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.